Author

M. A. Carpenter

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2 Cancer Biology· 2 Cell Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:human· 5 Assay:whole-genome sequencing· 2 Research Focus:cell type annotation· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

R. S. Harris· 5 shared H. Aihara· 2 shared W. L. Brown· 2 shared A. A. Jungbluth· 1 shared A. Gazzo· 1 shared A. Gupta· 1 shared A. Marra· 1 shared A. Safonov· 1 shared

Activity by Year

2019-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 26 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersBiochemistry

R. S. Harris

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

A real-time biochemical assay for quantitative analyses of APOBEC-catalyzed DNA deamination

C. A. Belica, M. A. Carpenter, Y. Chen, W. L. Brown, N. H. Moeller, I. T. Boylan, R. S. Harris, H. Aihara

The paper develops a real-time biochemical assay to quantify APOBEC3-catalyzed DNA deamination and identify inhibitors.

bioRxiv · May 11, 2024Biochemistry

APOBEC3 mutagenesis drives therapy resistance in breast cancer

A. Gupta, A. Gazzo, P. Selenica, A. Safonov, F. Pareja, E. M. da Silva, D. N. Brown, Y. Zhu, J. Patel, J. Blanco-Heredia, B. Stefanovska, M. A. Carpenter, X. Pei, D. Frosina, A. A. Jungbluth, , S. Chandarlapaty

This study identifies APOBEC3 mutagenesis as a common driver of therapy resistance in breast cancer, associated with poorer clinical outcomes.

bioRxiv · Apr 29, 2024Cancer Biology

APOBEC3 degradation is the primary function of HIV-1 Vif for virus replication in the myeloid cell line THP-1

T. Ikeda, R. Shimizu, H. Nasser, M. A. Carpenter, A. Z. Cheng, W. L. Brown, D. Sauter, R. S. Harris

This study shows that HIV-1 Vif primarily degrades A3 enzymes to enable viral replication in THP-1 cells, as disrupting A3 proteins restores infectivity of Vif-deficient viruses.

bioRxiv · Mar 28, 2023 · PreprintMicrobiology

Rad51 inhibition sensitizes non-replicating quiescent cells to UVB radiation and transcription stress

S. Khan, M. A. Carpenter, M. G. Kemp

The paper shows Rad51 promotes survival of quiescent cells under UVB and transcription stress, independent of NER.

bioRxiv · Sep 20, 2022 · PreprintCell Biology

Mutational impact of APOBEC3A and APOBEC3B in a human cell line and comparisons to breast cancer

M. A. Carpenter, N. A. Temiz, M. Ibrahim, M. Jarvis, M. Brown, P. Argyris, W. Brown, D. Yee, R. S. Harris

This study quantifies the mutagenic activities of APOBEC3A and APOBEC3B in a human cell line and compares their mutation signatures to breast cancer genomes, showing both enzymes contribute to the mutation landscape.

bioRxiv · Apr 26, 2022Cancer Biology

Active site plasticity and possible modes of chemical inhibition of the human DNA deaminase APOBEC3B

K. Shi, O. Demir, M. A. Carpenter, S. Banerjee, D. A. Harki, R. E. Amaro, R. S. Harris, H. Aihara

This study reports structures of APOBEC3B with loop 7 from APOBEC3G, revealing inactive conformations stabilized by small molecules, providing insights for inhibitor design.

bioRxiv · Jan 7, 2019Biochemistry